General Atlantic Portfolio
Our portfolio companies are already on a strong growth trajectory — our goal is to enhance it. We have a solid track record of delivering strategic, practical and impactful support to our portfolio companies.
Pharvaris ×
Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.